IN-CLASS TRANSITION (ICT) FROM PARENTERAL BORTEZOMIB...
IN-CLASS TRANSITION (ICT) FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB PROTEASOME INHIBITOR (PI) THERAPY INCREASES THE FEASIBILITY OF LONG-TERM PI TREATMENT AND BENEFIT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS IN AN OUTPATIENT SETTING: UPDATED REAL-WORLD RESULTS FROM THE COMMUNITY-BASED UNITED STATES (US) MM-6 STUDY
Long-term PI-based treatment is associated with improved outcomes in MM. Nonetheless, prolonged therapy with parenteral PIs (e.g. bortezomib) can be challenging in the real world, with median duration of therapy (DOT) of 4–7 months. Barriers to this long-term approach may include the burden of repeated intravenous/subcutaneous administration, difficulty travelling to/accessing treatment centers (e.g. due to environmental factors, travel restrictions, social/family situations), patient preference for treatment outside of a hospital or clinic setting, comorbidities, and toxicity. The US MM-6 study (NCT03173092) is investigating in-class transition (iCT) from parenteral bortezomib-based induction to all-oral ixazomib-based therapy (ixazomib-lenalidomide-dexamethasone; IRd) in the diverse US community population with the aim of increasing PI-based treatment duration while maintaining quality of life and improving outcomes. We report updated efficacy and safety for the first 101 patients.
Posted in Multiple Myeloma